Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Janux Therapeutics, Inc.NASDAQ: JANX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at 87.4%

Gross margin was 87.4% in Q1 FY2026. On a trailing-twelve-month basis it was 54.1%, up 476.2 pp year over year. Over 3 fiscal years it narrowed by 10.5 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
87.4%+100.9 pp QoQ
Last fiscal yearDec 2025
79.7%-0.8 pp YoY
LTMMar 2026
54.1%+476.2 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-0.8 pp——
3 years-10.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
79.7%
Year-over-year change
-0.8pp

Gross Margin vs competitors

How JANX compares with its peers on the latest reported figures

  • JANX's LTM Mar 2026 gross margin of 54.1% is the 7th highest of the 8 companies compared; the peer median is 69.9%.
  • Its year-over-year change of +476.2 pp is the 2nd highest of 8, against a peer median of +0.1 pp.
  • Over three fiscal years its change of -10.5 pp compares with a peer median of +10.6 pp.
JANX Competitors Peer median
Gross Margin for JANX and competitors
Company Period LTM level YoY 3-year change
IMTXImmatics N.V.LTM Mar 2026100.0% +0.1 pp+61.8 pp
CTMXCytomX Therapeutics, Inc.LTM Mar 202699.3% -0.7 pp+0.0 pp
STROSutro Biopharma, Inc.LTM Mar 202698.7% +1.4 pp+5.1 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
IMNMImmunome, Inc.FY202557.4% -42.6 pp—
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
JANXJanux Therapeutics, Inc.LTM Mar 202654.1% +476.2 pp-10.5 pp
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-662.5% +5797.5 pp+3489.9 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
VRXAVeraxa Biotech Holding AG—— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
Peer median (excluding JANX) 69.9%+0.1 pp+10.6 pp

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.